Tweeter button Delicious button Digg button Stumbleupon button
Monthly Archives: August 2013
Fatty Liver Disease | Research And Markets: Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H2 2013
fatty liver disease

DUBLIN–(BUSINESS WIRE)– Research and Markets ( ) has announced the addition of the “Non Alcoholic Fatty Liver Disease (NAFLD) – Pipeline Review, H2 2013” report to their offering. This report provides information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with latest updates, and special features on late-stage and discontinued projects. It also    .. more …

Facebook Twitter Email

Liver Disease | Galectin Therapeutics Receives FDA Fast Track Designation For GR-MD-02 For Fatty Liver Disease With Advanced Fibrosis
liver disease

NORCROSS, Ga., Aug. 12, 2013 (GLOBE NEWSWIRE) — Galectin Therapeutics ( GALT ), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted GR-MD-O2 (galactoarabino-rhamnogalacturonate) Fast Track designation for non-alcoholic steatohepatitis (NASH) with hepatic fibrosis, commonly    .. more …

Facebook Twitter Email

Hepatitis | Dealing With Cirrhosis Of The Liver Due To Hepatitis C
hepatitis

However, if you are listed for a transplant, you are given a Model for End-Stage Liver Disease (MELD) score. The lab values used in the MELD calculation include: Bilirubin, which measures how well your liver is excreting bile.INR, which measures your liver’s ability to make blood clotting factors.Creatine, which measures kidney function. Kidneys that aren’t functioning properly are often    .. more …

Facebook Twitter Email

Liver Diseases | Ocera Therapeutics Announces Completion Of Merger With Tranzyme
liver diseases

SAN DIEGO, July 15, 2013 (GLOBE NEWSWIRE) — Ocera Therapeutics, Inc. (“Ocera”), a clinical stage biopharmaceutical company developing novel therapeutics for orphan liver diseases, and Tranzyme, Inc. ( TZYM ) (“Tranzyme”) today announced that, following a special meeting of the shareholders of Tranzyme held on July 15, 2013, the Ocera and Tranzyme merger has closed. The combined company is named    .. more …

Facebook Twitter Email

Important Disclaimer: Article Comments provided are for general information purposes only and are not intended to substitute for informed professional medical, psychological, tax, accounting, legal, investment, or any other professional advice. We expressly disclaim liability for any product, manufacturer, distributor, service or service provider mentioned or any opinion expressed in these comments or anywhere else within the site. Lastly, we do not endorse any article or comment. Use at your own risk.